CN116585383A - 一种治疗排卵障碍性异常子宫出血的中药组合物及其药物制剂 - Google Patents
一种治疗排卵障碍性异常子宫出血的中药组合物及其药物制剂 Download PDFInfo
- Publication number
- CN116585383A CN116585383A CN202310453452.4A CN202310453452A CN116585383A CN 116585383 A CN116585383 A CN 116585383A CN 202310453452 A CN202310453452 A CN 202310453452A CN 116585383 A CN116585383 A CN 116585383A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- blood
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 79
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 230000002513 anti-ovulatory effect Effects 0.000 title claims abstract description 26
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 14
- 206010046788 Uterine haemorrhage Diseases 0.000 title description 9
- 206010027514 Metrorrhagia Diseases 0.000 claims abstract description 37
- 241000893536 Epimedium Species 0.000 claims abstract description 29
- 235000018905 epimedium Nutrition 0.000 claims abstract description 29
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 26
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 26
- 235000006533 astragalus Nutrition 0.000 claims abstract description 23
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 22
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 22
- 239000009910 sargent gloryvine Substances 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 claims abstract description 12
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 6
- 241000207925 Leonurus Species 0.000 claims description 25
- 241001061264 Astragalus Species 0.000 claims description 17
- 210000004233 talus Anatomy 0.000 claims description 17
- 241000207929 Scutellaria Species 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 7
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 5
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 206010010774 Constipation Diseases 0.000 claims description 3
- 206010051244 Dyschezia Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 239000005556 hormone Substances 0.000 abstract description 4
- 229940088597 hormone Drugs 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 240000007890 Leonurus cardiaca Species 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 88
- 239000008280 blood Substances 0.000 description 88
- 208000032843 Hemorrhage Diseases 0.000 description 41
- 208000034158 bleeding Diseases 0.000 description 39
- 230000000740 bleeding effect Effects 0.000 description 39
- 210000000952 spleen Anatomy 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 230000005906 menstruation Effects 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 230000002175 menstrual effect Effects 0.000 description 11
- 239000000583 progesterone congener Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000027758 ovulation cycle Effects 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 230000003821 menstrual periods Effects 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 8
- 230000023597 hemostasis Effects 0.000 description 8
- 230000001788 irregular Effects 0.000 description 8
- 208000005171 Dysmenorrhea Diseases 0.000 description 7
- 206010013935 Dysmenorrhoea Diseases 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 230000010415 tropism Effects 0.000 description 7
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- 244000183685 Citrus aurantium Species 0.000 description 5
- 235000007716 Citrus aurantium Nutrition 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 229940107666 astragalus root Drugs 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000004696 endometrium Anatomy 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000180649 Panax notoginseng Species 0.000 description 3
- 235000003143 Panax notoginseng Nutrition 0.000 description 3
- 241000405414 Rehmannia Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 230000000624 ovulatory effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 201000005670 Anovulation Diseases 0.000 description 2
- 206010002659 Anovulatory cycle Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000132012 Atractylodes Species 0.000 description 2
- 244000286838 Eclipta prostrata Species 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 241000830535 Ligustrum lucidum Species 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010041956 Stasis syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 231100000552 anovulation Toxicity 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 208000005634 blind loop syndrome Diseases 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 2
- 229960004913 dydrogesterone Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 201000006828 endometrial hyperplasia Diseases 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000007106 menorrhagia Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000906579 Actaea cimicifuga Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 241000234653 Cyperus Species 0.000 description 1
- 244000150195 Cyperus longus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000123589 Dipsacus Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061978 Genital lesion Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000745988 Phyllostachys Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000863514 Sabicea Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047998 Withdrawal bleed Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940104299 cimicifugae rhizoma Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中药技术领域,具体是一种治疗排卵障碍性异常子宫出血的中药组合物,由以下重量份的原料药制成:黄芪15‑45份、益母草15‑30份、大血藤15‑30份、枳壳9‑18份、淫羊藿9‑30份、炒黄芩9‑15份、三七3‑9份。本发明的中药组合物具有疗效确切,毒副作用小,成本低廉,便于推广应用的优势。鉴于排卵障碍性异常子宫出血患病人群数量较大,目前临床激素治疗效果欠佳,本发明提供的中药复方制剂具有良好的应用前景。
Description
技术领域
本发明涉及中药组合物技术领域,具体地说,是一种治疗排卵障碍性异常子宫出血的中药组合物及其药物制剂。
背景技术
排卵障碍性异常子宫出血(ovulatory dysfunction abnormal uterinebleeding,AUB-O)即因稀发排卵、无排卵和黄体功能不足,主要是由于下丘脑-垂体-卵巢轴(HPO轴)功能异常引起的来源于子宫腔的异常出血。AUB-O临床表现为月经周期紊乱、经期长短不一、经量不定或增多,甚至大量出血。AUB-O约占AUB的50%,常见于青春期、绝经过度期,生育期也可因多囊卵巢综合征(PCOS)、肥胖、高催乳素血症等疾病引起。
AUB-O的治疗原则,急性出血期尽快止血并纠正贫血;血止后调整月经周期,预防子宫内膜增生和AUB复发;有生育要求者还应促排卵治疗。由于AUB-O从初潮到绝经的各年龄段,不同年龄段的常见病因不同,临床表现多样,患者的需求也有差异,治疗时需要全面考量。
(一)青春期
青春期AUB-O的主要原因是HPO轴的精细调节尚未成熟,对雌激素变化不敏感,导致卵泡雌激素水平相对较低,不能形成排卵前的LH高峰,从而不能排卵,卵泡闭锁导致AUB。
1.出血期止血:可采用孕激素内膜脱落法、短效COC进行治疗。中华医学会妇产科分会2018年制定的《排卵障碍型异常子宫出血诊治指南》指出不推荐高效合成孕激素内膜萎缩法,因不良反应多;不推荐常规使用诊刮或宫腔镜检查,因子宫内膜病变的风险不高;仅在药物治疗效果不佳,不能除外子宫器质性病变时使用。
2.调整月经周期:推荐天然孕激素或地屈孕酮定期撤退法及使用短效COC,可连续使用3~6个月作为1个疗程,停药并观察效果,如AUB复发,可积极重新开始治疗。
(二)生育期
生育期AUB-O的常见原因有PCOS、肥胖、甲状腺功能异常等。
1.出血期止血:推荐短效COC治疗、孕激素内膜剥落法、高效合成孕激素内膜萎缩法。酌情将诊刮或宫腔镜检查、子宫内膜病理检查作为出血量多,需尽快止血的重要方法。
2.调整月经周期:(1)有生育要求者:希望尽快妊娠者可予促排卵,包括口服氯米芬、来曲唑,中药等。(2)无生育要求者:①短期内无生育要求者,可采用短效COC,既可以避孕,又可调整月经周期,并有治疗多毛、痤疮,缓解痛经等益处。②长期(超过1年)无生育要求者,可选择LNG-IUS;也可长期使用短效COC,可减少子宫内膜癌,卵巢恶性肿瘤等的发生率,并可避免反复发作的AUB-O。
(三)绝经过渡期
绝经过渡期AUB-O的主要原因是卵巢功能减退直至卵巢功能衰竭,导致稀发排卵或无排卵。绝经过渡期AUB-O易反复发生,且子宫内膜增生、子宫内膜癌的风险增加,需要长期管理。
1.出血期止血:中华医学会妇产科分会2018年制定的《排卵障碍型异常子宫出血诊治指南》推荐使用孕激素内膜脱落法、高效合成孕激素内膜萎缩法;不推荐大剂量(2~3片/d)短效COC止血,因可能增加绝经过渡期患者的血栓发生风险;推荐将诊刮或宫腔镜检查、子宫内膜病理检查作为怀疑有子宫内膜病变患者首次止血的治疗选择。
2.调整月经周期:(1)LNG-IUS:可长期、有效保护子宫内膜,显著减少月经出血量,并有效安全可靠的避孕效果,全身副作用较少。1次放置可维持5年,可作为绝经过渡期患者长期、安全、简便的选择,尤其适用于经量过多的患者。(2)孕激素定期撤退法:《排卵障碍型异常子宫出血诊治指南》推荐使用天然孕激素或地屈孕酮,不增加心血管疾病和乳腺癌的风险或风险较低,但需要长期管理,定期撤退出血,直到使用孕激素不能撤退出血,自然绝经为止。(3)伴有明确雌激素缺乏症状者,无性激素治疗禁忌证,可启动激素补充治疗,推荐天然雌激素与孕激素序贯治疗,有规律的撤退性出血,可同时缓解围绝经期症状。(4)短效COC:适用于经量多,有避孕需求,无使用禁忌证的患者,1片/d,21~24d,规范使用。
中医虽无“排卵障碍性异常子宫出血”这一病名,根据其临床表现,可归属于“崩漏”范畴。“崩漏”是指经血非时暴下不止或淋漓不尽。其中,出血量多如注而势急者为崩,又称为“崩中”、“血崩”等;出血量少淋漓不尽而势缓者为漏,又称为“漏下。”临床上,“崩”、“漏”虽有出血多少及病势急缓之分,但其病因病机一致,临床上常以“崩漏”并称。历代医家多从“虚、热、瘀”三个方面阐述其病因。其主要病机是劳伤气血,脏腑损伤,血海蓄溢失常,冲任二脉不能制约经血,以致经血非时而下。肾藏精,主生殖,为先天之本,肾气盛则天癸至;先天不足,则天癸不至,或迟至无序;房劳多产,则肾气虚,冲任不固,胞宫藏泻无度。脾为后天之本,化生气血,统摄血液,脾气主升,脾气亏虚,统摄无权,血失统摄,冲任不固而成“崩漏”。《妇科玉尺》云:“思虑伤脾,不能摄血,致令忘行。”素体阳盛,肝火易动;或素性抑郁,郁久化火;或感受热邪,热伏冲任,扰动血海,迫血妄行而成“崩漏”。《傅青主女科》云:“冲脉太热而血即沸,崩漏之为病,正冲脉之太热也”。情志所伤,肝气郁结,气滞血瘀;或经期、产后余血未尽,又感受寒、热之邪,寒凝血脉,或热灼津血而至血瘀,瘀阻冲任,旧血不去,新血难安,发为“崩漏”。
中医对“崩漏”治疗有其独特的方法,主要分为“塞流”、“澄源”、“复旧”三步。“塞流”,即在暴崩之际,急当止血防脱,首选补气摄血法。“澄源”,即正本清源,根据不同病因病机辨证论治以调整月经,正所谓“治病必求其本”;“复旧”,即固本善后,予调补肝肾,补益心脾,以资血源,安血之室,调周固本。近代以来,中医各医家采用经典方剂、自拟方或中成药治疗崩漏皆收获良好疗效。
发明内容
本发明的目的在于提供一种副作用小、可以长期服用的辅助治疗排卵障碍性异常子宫出血的中药组合物及其药物制剂。
为了实现上述目的,本发明的第一方面,提供一种治疗排卵障碍性异常子宫出血的中药组合物,由如下重量份的原料药制成:黄芪15-45份、益母草15-30份、大血藤15-30份、枳壳9-18份、淫羊藿9-30份、炒黄芩9-15份、三七3-9份。
进一步的,所述的治疗排卵障碍性异常子宫出血的中药组合物,由如下重量份的原料药制成:黄芪20-40份、益母草25-30份、大血藤25-30份、枳壳16-18份、淫羊藿15-30份、炒黄芩10-13份、三七4-7份。
更进一步的,所述的治疗排卵障碍性异常子宫出血的中药组合物,由如下重量份的原料药制成:黄芪30份、益母草30份、大血藤30份、枳壳18份、淫羊藿30份、炒黄芩12份、三七6份。
上述组合物中益母草为君药;黄芪、淫羊藿为臣药;大血藤、炒黄芩、枳壳、三七组合成佐药。
本发明的第二方面,提供一种以如上所述的治疗排卵障碍性异常子宫出血的中药组合物作为活性成份的药物制剂,所述的药物制剂是采用本领域常规制备方法制备成药剂学上的常用剂型。
进一步的,所述的药物制剂是颗粒剂、片剂、冲剂、散剂、胶囊剂、口服液或滴丸剂。
进一步的,所述的药物制剂中还包括药学上允许的辅料。
进一步的,所述的药物制剂可用以下方法制备得到:(A)称取所述各药材组份,混合,获得混合物;(B)在所述混合物中加入药学上可接受的载体,采用本领域常规制备方法制得。
本发明的第三方面,提供一种如上所述的中药组合物和药物制剂在制备治疗排卵障碍性异常子出血的药物中的应用。
本发明的给药量是治疗有效量,例如每天约2克/千克体-约5.5克/千克体重,较佳的剂量是约3克/千克体重-约4克/千克体重。一般用药时间为1-9月,较佳的为3-6月,更佳的为4-5月。当然,用药时间还要考虑给药途径、病人健康状况,这些都是熟练医师技能范围之内的。此外,本发明的中药组合物还可与西药或其他中成药等其他治剂一起使用。
本发明的组方中各项药物的性味、归经和功用,及常用重量如下:
益母草:为唇形科一年或二年生草本植物益母草的干燥地上部分。性味归经:辛、苦,微寒。归心、肝、膀胱经。功效:活血调经,利水消肿,清热解毒。主治:血瘀证;水肿,小便不利;热毒疮痈。孕妇忌用。常用量:10~30g。
黄芪:为豆科植物蒙古黄芪或膜荚黄芪的根。性味:甘,微温,归脾、肺经。功效:补气健脾,升阳举陷,益卫固表,利尿消肿,拖毒生肌。主治:脾气虚证,肺气虚证,气虚自汗,气血亏虚,疮疡难溃难腐,或溃久难敛。蜜灸可增强其补中益气作用。常用量9~30g。
淫羊藿:为小檗科植物淫羊藿和箭叶淫羊藿或柔毛淫羊藿等的全草。性味归经:辛、甘、温,归肾、肝经。功效:补肾壮阳,祛风除湿。主治:肾阳虚衰,阳痿尿频,腰膝无力,风寒湿痹,肢体麻木,常用量:3~15g。
黄芩,为唇形科多年草本植物黄芩的干燥根。性味归经:苦、寒。归肺、胆、脾、大肠、小肠经。功效:清热燥湿,泻火解毒,止血,安胎。主治:湿热证;脏腑实热证及少阳证;血热出血证;热毒证;胎动不安。清热多生用,安胎多炒用,清上焦热可酒灸用,止血可炒炭用。常用量:3~10g。
大血藤:为木通科落叶木质藤本植物大血藤的干燥藤茎。又称为红藤。性味归经:苦,平。归大肠,肝经。功效:清热解毒,活血止痛,祛风通络。主治:肠痈,皮肤疮痈;血瘀证;风湿痹通。常用量:9~15g。
三七:为五加科多年草本植物三七的干燥根和根茎。性味归经:甘、微苦,温。归肝、胃经。功效:化瘀止血,消肿止痛。主治:出血证;瘀血证;生用或研细粉用。研末吞服,1~3g;煎服,3~10g,亦入丸,散。
枳壳:为芸香科植物酸橙及其栽培变种的接近成熟的去瓤果实,生用或麸炒用。性味归经:苦、辛、微寒。归脾、胃、大肠经。功效:理气宽中,行滞消胀。主治:脾胃气滞,脘腹胀满,食积不化,痰饮内停,脏器下垂等。孕妇慎用。常用量:3~10g。
本发明所述的排卵障碍性异常子宫出血(AUB-O)是现代医学病名,主要表现为月经周期紊乱,经期长短不一,经量不定或增多,甚至大量出血,严重时可导致贫血、休克。中医根据其临床表现,将其归属于“崩漏”妇科疾病范畴。其病位在肝、脾、肾,其病因病机复杂,历代医家多认为“崩漏”的病机为虚、热、瘀,瘀血是“崩漏”的病理关键,瘀血不去,“崩漏”难止。“崩漏”的发生和发展常和气血同病。无论病起何脏,“四脏相移,必归脾肾”,故治疗“崩漏”化瘀止血之时需要辅以健脾补肾增强正气。本发明以此原则为依据,各味药材按君臣佐使比例相互配伍,起到化瘀止血以塞流,辅以补肾益气、清热解毒之效。临床予该中药组合物制成的汤药治疗AUB-O患者的,服用3-7天后,可达到止血之目的。
俞超芹教授认为“崩漏”基本病机为冲任损伤,不能制约经血。临床上,无论因虚、因热还是因瘀而致“崩漏”,最终均因瘀血留滞而致血不能自止。因此,瘀血是“崩漏”的病理关键,瘀血不去,崩漏不止,祛瘀是治疗大法。治疗“崩漏”应遵从三大要素,一、通因通用,活血止血而不留瘀;二、健脾补肾、摄血扶正,后天与先天同补;三、清热解毒,则可凉血止血、固本清源。方中君药,益母草具有活血祛瘀、清热解毒的作用,可治疗崩中漏下、月经不调、胎漏难产、胞衣不下,瘀血腹痛等,有“血家圣药”的美称。研究发现,益母草制剂有兴奋动物子宫的作用,与脑垂体后叶素相似,益母草浸膏及煎剂对子宫有强而持久的兴奋作用,不但能增强其收缩力,同时能提高其紧张度和收缩率。《傅青主女科》云:“血崩而至于黑暗昏晕,则血已尽去,仅存一线之气,以为护持。若不急补气以生血,而先补其血而遗气,则有形之血,恐不能遂生,而无形之气,必至尽散,此所以不先补其血而先补气也。”气为血之帅,血为气之母,血崩之际,气血同病,故本中药组合物重用黄芪作为臣药以补气摄血。黄芪性甘,微温,归脾、肺经,具有补气升阳之效。《医学衷中参西录》记载黄芪“能补气,兼能升气,善治胸中大气(即宗气)下陷”。肾气虚,封藏失司,冲任不固,不能制约经血,而致子宫藏泻失常。淫羊藿,又名仙灵脾,是补肾之要药。现代药理研究表明,淫羊藿的化学成分以黄酮类化合物为主,其有效成分具有雌激素样作用,可促进子宫内膜的快速修复。故本方以健脾补肾之黄芪、仙淫脾共为臣药。大血藤性味苦、平,具有清热解毒,活血通络等功效。现代药理学表明,大血藤具有抗菌,消炎,抗病毒、抗肿瘤、抗辐射等作用。“血崩”日久,热毒常常蕴结壅滞,入血入络,迫血妄行,灼伤脉络,血溢脉外,而见各种出血,血瘀表现。血热血瘀,常互为因果,正所谓“热附血而愈觉缠绵,血得热而愈形胶固”。叶天士在《温热论》中指出:“入血就恐耗血动血,直须凉血散血”,这为瘀和热两者相互作用所致的出血提供了很好的论据。黄宫绣《本草求真》指出:“其热不除,则血不止,其热既清,则血自安”。因此治疗“血崩”时需要清热解毒、凉血活血,本组方以炒黄芩清热凉血、大血藤清热解毒。枳壳,性微寒,味苦,辛、酸,归脾、胃经,具有行气消胀、宽中理气的作用。现代女性在面对工作、家庭、社会压力时,多忧思抑郁,气滞则血瘀;瘀血阻滞胞宫,血不归经;或肝郁化热,热扰冲任,迫血妄行,则见“崩漏”。临床上运用枳壳可以改善患者肝郁气滞现象。三七素有止血不留瘀,活血不伤正的特点,为止血良药,尤以出血兼有瘀滞者最为适宜。此数药联用,辅助君药活血止血不留瘀,清热调经兼解毒之效。总之,该中药组方活血止血以塞流,辅以清热益气而扶正,气血兼顾,清化兼施,寓攻于补,逐瘀而不伤正,补脾益气而不留瘀,使冲任得固,气血平和而病自愈。
本发明优点在于:
1、本发明提供的用于治疗AUB-O的中药组合物,所用原料价廉,制备简便,使用方便,副作用小,经多年临床应用和药理研究,对治疗排卵障碍性异常子宫出血具有较好的疗效。
2、本发明的中药组合物具有疗效确切,毒副作用小,成本低廉,便于推广应用的优势。鉴于AUB-O患病人群数量较大,目前临床激素治疗效果欠佳,本发明提供的中药复方制剂具有良好的应用前景。
附图说明
图1.治疗前后痛经VSA评分。
具体实施方式
下面结合实施例对本发明提供的具体实施方式作详细说明。
下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。本发明实施例所用药材除另有注明,均可以从中药材销售公司获得。所获得的药材除另有注明,均为中药材饮片。饮片既可以从销售公司获得,也可以是获得后经加工而成。
实施例1:本发明的中药组合物
由如下重量份的原料药组成:黄芪15份、益母草15份、大血藤15份、枳壳9份、淫羊藿9份、炒黄芩9份、三七3份。
实施例2:本发明的中药组合物
由如下重量份的原料药组成:黄芪20份、益母草20份、大血藤20份、枳壳12份、淫羊藿15份、炒黄芩10份、三七4份。
实施例3:本发明的中药组合物
由如下重量份的原料药组成:黄芪30份、益母草25份、大血藤25份、枳壳16份、淫羊藿20份、炒黄芩13份、三七6份。
实施例4:本发明的中药组合物
由如下重量份的原料药组成:黄芪40份、益母草30份、大血藤30份、枳壳18份、淫羊藿30份、炒黄芩12份、三七7份。
实施例5:本发明的中药组合物
由如下重量份的原料药组成:黄芪45份、益母草30份、大血藤30份、枳壳18份、淫羊藿25份、炒黄芩15份、三七9份。
实施例6:本发明的中药组合物
由如下重量份的原料药组成:黄芪30份、益母草30份、大血藤30份、枳壳18份、淫羊藿30份、炒黄芩12份、三七6份。
实施例7:本发明的汤剂制备
称取益母草30份、黄芪30份、淫羊藿30份、炒黄芩12份、大血藤30份、枳壳18份、三七6分。用水冲洗后于容器内浸泡2小时以上,常压煎煮20分钟后,滤出药液,得到本发明中药组合物的水煎剂。
实施例8:本发明的颗粒剂制备
称取益母草30份、黄芪30份、淫羊藿30份、炒黄芩12份、大血藤30份、枳壳18份、三七6分。用水冲洗后于容器内浸泡2小时以上,常压煎煮30分钟后,滤出药液,得到本发明中药组合物的水提取物,浓缩后加糊精,糖粉,混匀,以适量70%乙醇制软材,过1号筛制粒,50℃干燥2小时,干燥颗粒过12~14目筛整粒,分装,即得。
实施例9:本发明的片剂制备
称取益母草30份、黄芪30份、淫羊藿30份、炒黄芩12份、大血藤30份、枳壳18份、三七6分。用水冲洗后于容器内浸泡2小时以上,常压煎煮30分钟后,滤出药液,得到本发明中药组合物的水提取物,加微晶纤维素、淀粉混匀,加入适量70%乙醇制软材,过1号筛制粒,50℃干燥2小时,干燥颗粒过12~14目筛整粒,加入硬脂酸镁,混匀,压片,即得。
实施例10:本发明的临床试验
一般资料:病例收集自2021年6月至2021年10月间,以排卵障碍性异常子宫出血就诊于长海医院中医科妇科门诊的患者40例。其中13-20岁5例,占比12.5%;21-30岁14例,占比35%;31-40岁16人,占比40%;41岁-48岁5例,占比12.5%。淋漓不断21例,月经紊乱17例,月经量大10例。其中25例患者伴有痛经。40例患者均排除血液系统疾患,心、肝、肾功能正常。
诊断标准:(1)年龄13岁~48岁;(2)月经周期紊乱;(3)经期延长,阴道流血持续7天以上;(4)月经量多,血量200ml以上。全部患者均排除生殖器器质性病变、肝脏病变及血液系统疾病。且近3个月内未用激素类药物。
治疗方法:本组患者服用本发明所述的中药组合物,益母草30份、黄芪30份、淫羊藿30份、炒黄芩12份、大血藤30份、枳壳18份、三七6份。将上述中药冷水1000ml浸泡30分钟,再用武火煎煮,煮沸后文火煎30min,过滤取汁,每日一剂,早晚各1次,连服3~10剂,出血即止。
疗效标准:按中华人民共和国中医药行业标准,中医妇科病证诊断疗效标准。治愈:经量、经期、周期恢复正常,可维持3个月经周期;显效:经量、经期、周期虽恢复正常,但不能维持3个月经周期,或经量减少或经期缩短;无效:阴道出血无变化。
治疗结果:本组40例患者中,治愈27例(67.5%),显效9例(22.5%),无效4例(10%),总有效率为90%。其中月经淋漓不断21例,治疗后19例明显改善(19/21,有效率90.48%);月经紊乱17例,治疗后15例周期恢复正常(15/17,有效率88.24%);月经量大10例,治疗后9例月经量减少(9/10,有效率90%)。痛经VAS评分在治疗后也有显著改善,治疗前痛经VAS评分平均值5.44,治疗后痛经VAS评分平均值3.12,两者存在显著差异(p<0.001),如图1所示。
实施例11:本发明的经典个案
病案一
赵某某,女,47岁,已婚多产,自由职业。2019年8月6日初诊。主诉:诊刮术后阴道出血14天。
初诊:患者2019年7月23日因阴道不规则出血、超声提示子宫内膜增厚至当地医院行诊刮术,病理结果未回报。术后至今阴道流血不止,量多,血色鲜红,有血块,末次月经:6月20日。月经史:16岁初潮,经期6-7天净,周期28-35天,量色可。患者面色萎黄,舌唇淡白,头晕眼花,口干,五心烦热,心悸少寐,腰膝酸软,脉细数,乏力,胃纳差,大小便均正常。证由瘀阻子宫,血不归经而妄行。崩漏日久,气血亏虚,肾阴不足,虚热扰动血海,治以消瘀遏流,治其标;治标同时补养脾肾固其本。药用:益母草30份、黄芪30份、淫羊藿30份、炒黄芩12份、大血藤30份、枳壳18份、三七6份,7付,水煎服,早晚各1次。患者服上药4剂后血止,精神软,面色萎黄,胃纳较前好转,睡眠可,大便质稀,量少,2~3天一行,小便调,舌淡红,苔薄白,脉细数。患者虽已血止,但气血未复,治以益气补肾,巩固止崩。方药:地黄12g、熟地黄12g、白芍9g、全当归9g、黄精15g、莪术9g、石菖蒲15g、女贞子12g、旱莲草12g、黄芪30g、茯苓15g、生白术15g、升麻6g,柴胡6g,知母9g,7付,水煎服,早晚各1次。
病案二
患者王某,女,25岁,办公室人员,2019年5月31日初诊。主诉:阴道不规则出血8天。
患者14岁月经初潮,初潮后月经长期不规则,周期短则半月一行,长则3个月一行,量少,淋漓不净,持续10~20余天不等,既往有PCOS病史,曾口服优思明治疗3个月,服药期间月经规则,停药后月经再次紊乱,易不规则阴道出血。LMP:2019年5月7日,量色可,有少量血块,无痛经表现,7天净。5月23日无明显诱因再次有阴道有大量出血,持续至今,色暗红,痛经(-),血块(+),舌质紫暗,苔黄,脉细涩,口干,平常性情易焦虑,思虑过多,头发脱落较多,腰膝酸软,乏力,胃纳可,少寐,大便偏稀,2~3次/日,小便正常。否认有性生活史。妇科检查正常。此时治疗应通因通用,依势通下,活血化瘀以止血,辅以清热益气养阴。方药:益母草30份、黄芪30份、淫羊藿30份、炒黄芩12份、大血藤30份、枳壳18份、三七6份,7付,水煎服,早晚各1次。患者服上药3付后血止,腰酸症状较前好转,胃纳可,睡眠可,二便调,舌稍红,少苔,脉弦细。此时治疗应以调理月经周期为主,补益气血以复旧。方药:黄芪30g、太子参15g、升麻6g、柴胡6g、炒白术15g、熟地30g、山萸肉15g、杜仲15g、续断15g、女贞子15g、旱莲草15g、香附9g,7付,水煎服,早晚各1次。
以上已对本发明创造的较佳实施例进行了具体说明,但本发明创造并不限于所述实施例,熟悉本领域的技术人员在不违背本发明创造精神的前提下还可做出种种的等同的变型或替换,这些等同的变型或替换均包含在本申请权利要求所限定的范围内。
Claims (8)
1.一种治疗排卵障碍性异常子宫出血的中药组合物,其特征在于,由如下重量份的原料药制成:黄芪15-45份、益母草15-30份、大血藤15-30份、枳壳9-18份、淫羊藿9-30份、炒黄芩9-15份、三七3-9份。
2.根据权利要求1所述的治疗排卵障碍性异常子宫出血的中药组合物,其特征在于,由如下重量份的原料药制成:黄芪20-40份、益母草25-30份、大血藤25-30份、枳壳16-18份、淫羊藿15-30份、炒黄芩10-13份、三七4-7份。
3.根据权利要求1所述的治疗排卵障碍性异常子宫出血的中药组合物,其特征在于,由如下重量份的原料药制成:黄芪30份、益母草30份、大血藤30份、枳壳18份、淫羊藿30份、炒黄芩12份、三七6份。
4.一种以权利要求1-3任一所述的治疗排卵障碍性异常子宫出血的中药组合物作为活性成份的药物制剂,其特征在于,所述的药物制剂是采用本领域常规制备方法制备成药剂学上的常用剂型。
5.根据权利要求4所述的药物制剂,其特征在于,所述的药物制剂是颗粒剂、片剂、冲剂、散剂、胶囊剂、口服液或滴丸剂。
6.根据权利要求4所述的药物制剂,其特征在于,所述的药物制剂中还包括药学上允许的辅料。
7.一种如权利要求1-3任一所述的中药组合物在制备治疗排卵障碍性异常子出血的药物中的应用。
8.一种如权利要求4-6任一所述的药物制剂在制备治疗排卵障碍性异常子出血的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310453452.4A CN116585383A (zh) | 2023-04-25 | 2023-04-25 | 一种治疗排卵障碍性异常子宫出血的中药组合物及其药物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310453452.4A CN116585383A (zh) | 2023-04-25 | 2023-04-25 | 一种治疗排卵障碍性异常子宫出血的中药组合物及其药物制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116585383A true CN116585383A (zh) | 2023-08-15 |
Family
ID=87589036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310453452.4A Pending CN116585383A (zh) | 2023-04-25 | 2023-04-25 | 一种治疗排卵障碍性异常子宫出血的中药组合物及其药物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116585383A (zh) |
-
2023
- 2023-04-25 CN CN202310453452.4A patent/CN116585383A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102228603B (zh) | 一种治疗尿潴留的中药 | |
CN106334060B (zh) | 一种治疗肥胖型多囊卵巢综合征的药物组合物 | |
CN103432559B (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
CN110917326A (zh) | 一种促进子宫内膜修复中药组合物及其应用 | |
CN115770279B (zh) | 用于治疗慢性下肢静脉疾病的中药组合物及其汤剂和制剂 | |
CN103977281A (zh) | 一种治疗女性内分泌失调的中药组合物及其制备方法 | |
CN103432419A (zh) | 一种治疗功能失调性子宫出血病的中药组合物及其制剂的制备方法 | |
CN110613777A (zh) | 一种治疗痰湿阻滞型多囊卵巢综合征的中药组合物 | |
CN107737288B (zh) | 一种治疗过敏性哮喘的中药组合物及其制备方法 | |
CN104873706A (zh) | 一种治疗宫寒不孕症的中药组合物 | |
CN116585383A (zh) | 一种治疗排卵障碍性异常子宫出血的中药组合物及其药物制剂 | |
CN112704723A (zh) | 一种治疗妇科痛经的中药制剂及其制法 | |
CN105233078A (zh) | 一种用于治疗病毒性肝炎的中药组合物 | |
CN105343847A (zh) | 一种含有艾叶的治疗湿疹的中药组合物及其制备方法 | |
CN105106696A (zh) | 一种治疗慢性前列腺炎的中药组合物 | |
CN104288581A (zh) | 用于治疗先兆流产的中药 | |
CN104547489A (zh) | 一种中药组合物在制备治疗粉碎性骨折药物中的用途 | |
CN104491670A (zh) | 一种治疗慢性盆腔炎的中药组合物 | |
CN103301373A (zh) | 一种治疗产后会阴粘膜病变的药物组合物 | |
CN102988630A (zh) | 一种治疗痛风病的药物组合物及其制备方法 | |
CN115624605B (zh) | 一种治疗卵巢型子宫内膜异位症的中药组合物 | |
CN101371912A (zh) | 一种治疗痛经的中药口服汤剂 | |
CN105663850A (zh) | 一种治疗口腔溃疡的中药组合物 | |
CN105412706A (zh) | 一种治疗女性内分泌失调的中药组合物 | |
CN103919981A (zh) | 一种治疗无菌性前列腺炎的中药混合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |